Immunic, Inc. IMUX
Set alert
7.51 USD -0.29 -3.66%
At close · Oct 30
7.62 +0.11 +1.46%
After hours · Oct 30, 5:43 PM ET
7.37 Day range 7.78
5.10 52-week range 16.90
- YTD
- +40.64%
- 1 year
- -4.21%
- Open
- 7.70
- Prev close
- 7.80
- Mkt cap
- 102.47M
- Vol
- 244.43K
- Avg vol
- 335.47K
- EPS
- -3.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.37
- High
- 7.78
- Forward P/E
- -1.67
- Beta
- 1.88
- Short ratio
- 4.69
- Inst. own
- 64.85%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.24
- 200-d avg
- 1.32
- 1y target
- 12.79
2Y chart
Events in this range
- Nov 7, 2024Rating: EF Hutton · Buy → Buy
- Nov 7, 2024Earnings: -0.24; estimate -0.22; surprise -9.09%
- Nov 25, 2024Rating: HC Wainwright & Co. · — → Buy
- Apr 27, 2026Split: 1 for 10
Signals (90)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| SMA: Bearish | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| RSI: Overbought | Mar 6, 2026 | 7 months ago |
| RSI: Overbought | Mar 2, 2026 | 8 months ago |
| RSI: Overbought | Feb 19, 2026 | 8 months ago |
| RSI: Overbought | Feb 13, 2026 | 8 months ago |
| SMA: Bullish | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| SMA: Bearish | Jan 27, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 14, 2026 | 9 months ago |
| SMA: Bullish | Jan 13, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 18, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 20, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| SMA: Bearish | Oct 14, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| SMA: Bearish | Oct 7, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 17, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| SMA: Bullish | Aug 14, 2025 | 1 year ago |
| SMA: Bearish | Aug 13, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| RSI: Overbought | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| RSI: Oversold | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 8, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 1, 2025 | 1 year ago |
| SMA: Bearish | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| SMA: Bearish | Apr 3, 2025 | 1 year ago |
| SMA: Bullish | Apr 2, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 25, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 10, 2025 | 1 year ago |
| RSI: Overbought | Feb 21, 2025 | 1 year ago |
| SMA: Bullish | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 6, 2025 | 1 year ago |
Key statistics
- Market cap
- 96.38M
- Enterprise value
- 31.91M
- Trailing P/E
- 0.00
- Forward P/E
- -1.67
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.34
- EPS (TTM)
- -1.23
- Beta
- 1.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -45.13M
- Total cash
- 59.07M
- Total debt
- 899.00K
- Return on equity
- -216.24%
- Shares outstanding
- 90.08M
- Short % of float
- 4.70%
- 50-day average
- 1.24
- 200-day average
- 1.32
Analyst view
Consensus: none
Price target (mean) 12.79 +70.2% upside
Now 7.51
- Target (low)
- 5.00
- Target (mean)
- 12.79
- Target (high)
- 28.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.23857.
Financials — quick view
IMUX Revenue — quarterly 0
IMUX Net income — quarterly -34.10M
IMUX EPS — quarterly -0.80
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.22 | -0.24 | -0.02 | -9.09% |
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | -0.21 | +0.02 | +8.70% |
| May 8, 2024 | Mar 1, 2024 | -0.27 | -0.25 | +0.02 | +7.41% |
| Feb 22, 2024 | Dec 1, 2023 | -0.51 | -0.48 | +0.03 | +5.88% |
| Nov 14, 2023 | Sep 1, 2023 | -0.55 | -0.51 | +0.04 | +7.27% |
| Aug 3, 2023 | Jun 1, 2023 | -0.52 | -0.54 | -0.02 | -3.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | init | — | Buy |
| Nov 7, 2024 | EF Hutton | main | Buy | Buy |
| Oct 22, 2024 | EF Hutton | main | Buy | Buy |
| Sep 18, 2024 | EF Hutton | main | Buy | Buy |
| Sep 16, 2024 | EF Hutton | init | — | Buy |
| Aug 27, 2024 | B. Riley Securities | init | — | Buy |
About Immunic, Inc.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- imux.com
News
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
- Cantor Fitzgerald Initiates Coverage On Immunic with Overweight Rating
- New Strong Buy Stocks for October 22nd
- Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
- Immunic adds new Chief People Officer ahead of Phase 3 readout
- Immunic Appoints Jaa Roberson as Chief People Officer
- Immunic, Inc. (NASDAQ:IMUX) Stock Has Consensus Target Price of $35.43 According to Analysts
- Immunic to present four vidofludimus calcium abstracts at MSToronto2026
- Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting
- Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Your note
Sign in to keep a note on IMUX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RUDICK RICHARD ALAN | Director | Purchase | Nov 11, 2024 | 87,300 |
| VITT DANIEL | Chief Executive Officer | Purchase | Feb 25, 2024 | 0 |
| WHALEY GLENN | Chief Financial Officer | Purchase | May 14, 2023 | 25,510 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.88% | 8,902,972 | 9.53M | Sep 29, 2024 |
| Avidity Partners Management, LP | 9.18% | 8,266,000 | 8.84M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 8.10% | 7,293,007 | 7.80M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.21% | 5,594,406 | 5.99M | Sep 29, 2024 |
| Janus Henderson Group PLC | 5.66% | 5,099,278 | 5.46M | Sep 29, 2024 |
| Vanguard Group Inc | 5.22% | 4,700,016 | 5.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.92% | 2,629,603 | 2.81M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 2.08% | 1,870,577 | 2.00M | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.22% | 202,245 | 216.40K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 190,000 | 203.30K | Sep 29, 2024 |
| Vanguard Balanced Index Fund | 0.11% | 98,039 | 104.90K | Sep 29, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.08% | 69,930 | 74.83K | Sep 29, 2024 |